retatrutide phase 3 trial dosage just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric Lilly's triple agonist, retatrutide, delivered

The rising global prevalence of T2DM and obesity makes understanding the full range of benefits and risks associated with GLP-1 RAs essential for optimizing treatment strategies in these populations

Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity

The absence of additive benefit across most clinical outcomes in the comparison between GLP-1RA plus SGLT2i and GLP-1RA monotherapy suggests that the observed effect may be predominantly driven by GLP-1RA alone, rather than a synergistic effect of the combination

Retatrutide is a synthetic peptide built from 39 amino acids

Uname:Linux sio.dnshigh.com 5.14.0-687.24.1.el9_8.x86_64 #1 SMP PREEMPT_DYNAMIC Thu Jul 9 18:14:06 EDT 2026 x86_64